← Back to Clinical Trials
Recruiting NCT03639285

NCT03639285 Natural History, Diagnosis, and Outcomes for Leukodystrophies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03639285
Status Recruiting
Phase
Sponsor University of Utah
Condition Leukodystrophy
Study Type OBSERVATIONAL
Enrollment 600 participants
Start Date 2007-01-19
Primary Completion 2033-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 600 participants in total. It began in 2007-01-19 with a primary completion date of 2033-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goals of this protocol is to diagnose, care for, and understand the clinical histories and outcomes of people with leukodystrophies.

Eligibility Criteria

Inclusion Criteria: * evidence by clinical exam, radiological findings, and/or testing, of an inherited leukodystrophy. * be able to travel to the leukodystrophy clinic (at Primary Children's Hospital, Salt Lake City, Utah); * be able to tolerate a general physical exam, and a neurological exam. Exclusion Criteria: * unable to be evaluated at the University of Utah Hospital or Primary Children's Hospital; * refusal to sign study consent form; * evidence or finding of another non-genetic cause of their condition; * Persons with known white matter disease or lesions related to: birth injury or prenatal injury, multiple sclerosis, trauma, infection, immunization, or post-infectious effects (e.g. ADEM- acute disseminated encephalomyelitis), metabolic disturbance (e.g. Central pontine myelinolysis), neoplasms, primary rheumatologic diseases (e.g. Systemic lupus erythematosis), stroke, hypoxic-ischemic injury, drug or toxin effect, seizures, or endocrine disturbance.

Contact & Investigator

Central Contact

Josh Bonkowsky, MD, PhD

✉ joshua.bonkowsky@hsc.utah.edu

📞 8012133599

Frequently Asked Questions

Who can join the NCT03639285 clinical trial?

This trial is open to participants of all sexes, studying Leukodystrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03639285 currently recruiting?

Yes, NCT03639285 is actively recruiting participants. Contact the research team at joshua.bonkowsky@hsc.utah.edu for enrollment information.

Where is the NCT03639285 trial being conducted?

This trial is being conducted at Salt Lake City, United States.

Who is sponsoring the NCT03639285 clinical trial?

NCT03639285 is sponsored by University of Utah. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology